(UroToday.com) The treatment for metastatic hormone-sensitive prostate cancer plenary session at the European Association of Urology 2021 Annual Meeting included a presentation by Dr. Christopher Sweeney discussing when and how to use systemic treatment for recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney notes that the hypothesis is that men with mHSPC have a wide array of prognoses (i) that can be easily defined by clinical variables, (ii) impacts the efficacy of different treatment strategies, and (iii) have broadly distinct underlying biological profiles.